000302855 001__ 302855
000302855 005__ 20251019023155.0
000302855 0247_ $$2doi$$a10.1038/s41416-025-03116-z
000302855 0247_ $$2pmid$$apmid:40665014
000302855 0247_ $$2ISSN$$a0007-0920
000302855 0247_ $$2ISSN$$a1532-1827
000302855 0247_ $$2altmetric$$aaltmetric:179664194
000302855 037__ $$aDKFZ-2025-01395
000302855 041__ $$aEnglish
000302855 082__ $$a610
000302855 1001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa$$b0$$eFirst author$$udkfz
000302855 245__ $$aFatigue in long-term cancer survivors: prevalence, associated factors, and mortality. A prospective population-based study.
000302855 260__ $$aEdinburgh$$bNature Publ. Group$$c2025
000302855 3367_ $$2DRIVER$$aarticle
000302855 3367_ $$2DataCite$$aOutput Types/Journal article
000302855 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1760704057_429533
000302855 3367_ $$2BibTeX$$aARTICLE
000302855 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302855 3367_ $$00$$2EndNote$$aJournal Article
000302855 500__ $$a#EA:C070#EA:C071#LA:C070#LA:C071# / 2025 Oct;133(6):831-843
000302855 520__ $$aWe compared fatigue severity in breast, prostate or colorectal cancer survivors 5-16 years post-diagnosis with cancer-free controls, and examined factors associated with fatigue and its association with all-cause mortality in survivors.Participants of the CAncEr Survivorship - A multi-Regional (CAESAR) study completed the Fatigue Assessment Questionnaire (FAQ) between 2009 and 2011. The FAQ assesses affective, cognitive, and physical fatigue, and sleep problems. We derived the odds of fatigue using logistic regression with the 75th percentile of population norms as the cut-off. All-cause mortality (up to end 2021) was estimated using Cox regression models.The sample comprised 6057 survivors, of whom approximately one-third reported affective, cognitive, or physical fatigue. Demographic (age, relationship), clinical (chemotherapy), comorbidity (depression), lifestyle, and psychological factors were associated with higher odds of fatigue symptoms and total fatigue. Fatigue symptoms, predominantly physical fatigue, were strongly associated with mortality (unadjusted hazard ratios (HRs) ranged from 1.48 to 2.40). The HRs were attenuated after adjustment for comorbidities and depressive symptoms, although affective and physical fatigue remained independent risk factors for mortality.Demographic, clinical, comorbidity, lifestyle, and psychological factors were associated with fatigue in long-term survivors. Fatigued survivors have a higher mortality risk. Lowering the burden of fatigue by a comprehensive approach might result in better survival.
000302855 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000302855 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302855 7001_ $$0P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDoege, Daniela$$b1$$udkfz
000302855 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b2$$udkfz
000302855 7001_ $$aBertram, Heike$$b3
000302855 7001_ $$00000-0003-4195-5236$$aEberle, Andrea$$b4
000302855 7001_ $$aHolleczek, Bernd$$b5
000302855 7001_ $$00000-0002-7115-5160$$aNennecke, Alice$$b6
000302855 7001_ $$00000-0002-5909-9936$$aWaldmann, Annika$$b7
000302855 7001_ $$00000-0002-0743-6128$$aZeissig, Sylke Ruth$$b8
000302855 7001_ $$00000-0002-2858-2941$$aPritzkuleit, Ron$$b9
000302855 7001_ $$00000-0002-2648-2728$$aBrähler, Elmar$$b10
000302855 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b11$$udkfz
000302855 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b12$$eLast author$$udkfz
000302855 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-025-03116-z$$n6$$p831-843$$tBritish journal of cancer$$v133$$x0007-0920$$y2025
000302855 909CO $$ooai:inrepo02.dkfz.de:302855$$pVDB
000302855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000302855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000302855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000302855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000302855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000302855 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000302855 9141_ $$y2025
000302855 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-19$$wger
000302855 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2022$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-19
000302855 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2022$$d2024-12-19
000302855 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000302855 9202_ $$0I:(DE-He78)C071-20160331$$kC071$$lCancer Survivorship$$x1
000302855 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000302855 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lCancer Survivorship$$x1
000302855 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000302855 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000302855 9200_ $$0I:(DE-He78)C071-20160331$$kC071$$lCancer Survivorship$$x1
000302855 980__ $$ajournal
000302855 980__ $$aVDB
000302855 980__ $$aI:(DE-He78)C070-20160331
000302855 980__ $$aI:(DE-He78)C071-20160331
000302855 980__ $$aI:(DE-He78)HD01-20160331
000302855 980__ $$aUNRESTRICTED